IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1473-1484

  Burkhardt, Ute E ^a   Sloots, Arjen ^a   Jakobi, Vera ^a   Wei, Wei Zen ^b   Cavallo, Federica ^c   Kloke, Björn Philipp ^a   Wels, Winfried S ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b WAYNE STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Cancer vaccine; CTLA 4; ErbB2 transgenic mice; ErbB2 HER2; IL 15

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HYBRID PROTEIN; INTERLEUKIN 15;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMA CELL; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; EPITHELIUM CELL; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INOCULATION; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REJECTION;

ANIMALS; ANTIGEN-PRESENTING CELLS; CANCER VACCINES; CARCINOMA, RENAL CELL; CTLA-4 ANTIGEN; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-15; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 84866564182     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1215-7     Document Type: Article

References (47)

1. Pejawar-Gaddy S, Finn OJ (2008) Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 67:93-102
2. Keler T, He L, Ramakrishna V, Champion B (2007) Antibodytargeted vaccines. Oncogene 26:3758-3767
3. Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendriticcell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790-802. doi:10.1038/nri2173 (Pubitemid 47480309)
4. Romani N, Thurnher M, Idoyaga J, Steinman RM, Flacher V (2010) Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 88:424-430
5. Palucka K, Banchereau J, Mellman I (2010) Designing vaccines based on biology of human dendritic cell subsets. Immunity 33:464-478
6. Rohrbach F, Weth R, Kursar M, Sloots A, Mittrücker HW, Wels WS (2005) Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity. J Immunol 174:5481-5489 (Pubitemid 40593188)
7. Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jäger E, Forni G, Cavallo F, Wels WS (2008) DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Clin Cancer Res 14:6933-6943. doi:10.1158/1078-0432.CCR-08-1257
8. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354 (Pubitemid 40637826)
9. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475. doi:10.1038/nrc2656
10. Esteva FJ, Yu D, Hung MC, Hortobagyi GN (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7:98-107
11. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S (2008) Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 14:797-803 (Pubitemid 351231162)
12. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Link J, Waisman J, Salazar LG (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27:4685-4692. doi: 10.1200/JCO.2008.20.6789
13. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27:5911-5918. doi:10.1200/JCO.2009. 23.3494
14. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589-596 (Pubitemid 28369147)
15. Piechocki MP, Ho YS, Pilon S, Wei WZ (2003) Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 171:5787-5794 (Pubitemid 37467194)
16. Jacob JB, Quaglino E, Radkevich-Brown O, Jones RF, Piechocki MP, Reyes JD, Weise A, Amici A, Wei WZ (2010) Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity. Cancer Res 70: 119-128. doi:10.1158/0008-5472.CAN-09-2554
17. Waldmann TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6:595-601. doi:10.1038/nri1901 (Pubitemid 44134092)
18. Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Cole DJ (2002) Systemic administration of IL-15 augments the antigen-specific primary CD8? T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol 169:4928-4935 (Pubitemid 35217158)
19. Pulendran B, Dillon S, Joseph C, Curiel T, Banchereau J, Mohamadzadeh M (2004) Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8? Tc1 responses in vivo. Eur J Immunol 34:66-73. doi:10.1002/eji. 200324567 (Pubitemid 38111521)
20. Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, Palucka AK (2007) IL-15-induced human DC efficiently prime melanoma-specific naive CD8? T cells to differentiate into CTL. Eur J Immunol 37:1678-1690 (Pubitemid 46939501)
21. Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B (1988) Prolactin regulation of beta-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J 7:2089-2095
22. Maurer-Gebhard M, Schmidt M, Azemar M, Altenschmidt U, Stöcklin E, Wels W, Groner B (1998) Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 58:2661-2666 (Pubitemid 28275441)
23. Demaison C, Parsley K, Brouns G, Scherr M, Battmer K, Kinnon C, Grez M, Thrasher AJ (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13:803-813. doi:10.1089/10430340252898984 (Pubitemid 34493974)
24. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15:871-875. doi:10.1038/ nbt0997-871
25. Sloots A, Wels WS (2005) Recombinant derivatives of the human high-mobility group protein HMGB2 mediate efficient nonviral gene delivery. FEBS J 272:4221-4236. doi:10.1111/j.1742-4658.2005.04834.x (Pubitemid 41160928)
26. Schultz-Thater E, Noppen C, Gudat F, Durmuller U, Zajac P, Kocher T, Heberer M, Spagnoli GC (2000) NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer 83:204-208 (Pubitemid 30411718)
27. Harwerth IM, Wels W, Marte BM, Hynes NE (1992) Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. J Biol Chem 267:15160-15167
28. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Furukawa K, Kanematsu T, Shiku H (1997) Peptides derived from a wild-type murine proto-oncogene c-erbB-2/ HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159:1336-1343 (Pubitemid 127484112)
29. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of ''self''-reactive, tumoricidal T cells using highaffinity, altered peptide ligand. J Exp Med 188:277-286 (Pubitemid 28357756)
30. Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, Wels WS (2005) Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br J Cancer 92:1421-1429 (Pubitemid 40705009)
31. Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ (2008) Interleukin-15/ interleukin-15R alpha complexes promote destruction of established tumors by reviving tumorresident CD8? T cells. Cancer Res 68:2972-2983. doi: 10.1158/0008-5472.CAN-08-0045 (Pubitemid 351556298)
32. Zhang M, Yao Z, Dubois S, Ju W, Muller JR, Waldmann TA (2009) Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci USA 106:7513-7518. doi: 10.1073/pnas.0902637106
33. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422
34. Freeman GJ, Borriello F, Hodes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg JM, Hathcock K, Laszlo G et al (1993) Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 178:2185-2192 (Pubitemid 23344876)
35. Butler SP, O'Sickey TK, Lord ST, Lubon H, Gwazdauskas FC, Velander WH (2004) Secretion of recombinant human fibrinogen by the murine mammary gland. Transgenic Res 13:437-450 (Pubitemid 39431772)
36. Hynes NE, Taverna D, Harwerth IM, Ciardiello F, Salomon DS, Yamamoto T, Groner B (1990) Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells. Mol Cell Biol 10:4027-4034
37. Brandt R, Wong AM, Hynes NE (2001) Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene 20:5459-5465. doi:10.1038/sj.onc.1204709 (Pubitemid 32889482)
38. Steel JC, Ramlogan CA, Yu P, Sakai Y, Forni G, Waldmann TA, Morris JC (2010) Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res 70:1072-1081. doi:10.1158/0008-5472.CAN-09- 1301
39. Porzia A, Lanzardo S, Citti A, Cavallo F, Forni G, Santoni A, Galandrini R, Paolini R (2010) Attenuation of PI3 K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J Immunol 184:4170-4177. doi:10.4049/jimmunol.0903375
40. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M (2009) Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 106:3294-3299. doi:10.1073/pnas.0812059106
41. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8:1720-1730 (Pubitemid 34633727)
42. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-446. doi:10.1038/74704 (Pubitemid 30208162)
43. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM (2008) Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fcmediated activation of DCs. J Clin Invest 118:1700-1711. doi: 10.1172/JCI34333 (Pubitemid 351632374)
44. Radkevich-Brown O, Jacob J, Kershaw M, Wei WZ (2009) Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice. Cancer Res 69:212-218. doi: 10.1158/0008-5472.CAN-08-3092
45. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, Tan X, Sutton SE, Cooke MP, Ohlen C, Greenberg PD (2006) Interleukin-15 rescues tolerant CD8? T cells for use in adoptive immunotherapy of established tumors. Nat Med 12:335-341. doi:10.1038/nm1359 (Pubitemid 43355083)
46. Rolla S, Nicolo C, Malinarich S, Orsini M, Forni G, Cavallo F, Ria F (2006) Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 177:7626-7633 (Pubitemid 44846277)
47. Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL (2005) Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8? memory cell pool. J Clin Invest 115:1177-1187. doi:10.1172/JCI23134 (Pubitemid 40629036)